EP3654989
Notkun á kladribín til meðhöndlunar á sjálfsnæmis taugavöðvasjúkdómi
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
28.6.2018EP published:
3.1.2024EP application number:
18739593.4
EP translation filed:
11.3.2024Grant published:
15.4.2024EPO information:
European Patent Register
Max expiry date:
27.6.2038Expiry date:
27.6.2026Next due date:
30.6.2026
Title in English:
USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASELanguage of the patent:
English
Timeline
Today
28.6.2018EP application
3.1.2024EP Publication
11.3.2024Translation submitted
15.4.2024Registration published
27.6.2026Expires
Owner
Name:
Chord Therapeutics SAAddress:
c/o ARES TRADING SA Terre Bonne Business Park Route de Crassier 1, 1262 Eysins, CH
Inventor
Name:
REJDAK, KonradAddress:
20-882 Lublin, PL
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201711800Date:
21.7.2017Country:
GB
Classification
Categories:
A61K 31/7076, A61P 21/04, A61P 37/06
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 7.5.2024
Expires: 27.6.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 16.6.2025
Expires: 27.6.2026
Payer: Árnason Faktor ehf.